Hedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology ...

Investing.com -- Shares of Portage Biotech Inc. (NASDAQ: PRTG) surged 29% following the presentation of new preclinical data for its mesothelioma treatment, PORT-7. The company unveiled these findings ...

Biliary Tract Cancer (BTC): KEYTRUDA may be combined with chemotherapy medicines to treat BTC, a cancer that affects the bile ducts or gallbladder. This treatment is for adults when the cancer has ...

Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model. In the Thursday late trading session, the ...

Combining PORT-6 and PORT-7 for a More Comprehensive Immunotherapy Approach ...

A Wigan woman is calling for there to be urgent funding to Asbestos research in memory of her dad. MPs and Lords held a ...

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data ...

Portage Biotech (PRTG) presented new preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor. The new data demonstrate both ...

The development of surgical treatments for mesothelioma has followed a path similar to that of other solid tumors. The functional approach to treating solid tumors is a two-step process ...

Critical Path Institute® (C-Path) and Boston Medical Center (BMC) published results for six biomarkers that could improve the early and accurate detection of kidney injury, leading to both the ...

Shares of Portage Biotech Inc. more than doubled in after-hours trading on Thursday as the company reported promising ...

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...